{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:40:25Z","timestamp":1786542025364,"version":"build-2736575974"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Platinum-based chemotherapy remains a key component of lung cancer treatment. Although carboplatin and cisplatin are widely used, their real-world adverse-event reporting profiles may differ. This study compared carboplatin- and cisplatin-associated safety signals in lung cancer using the FDA Adverse Event Reporting System (FAERS), with emphasis on organ-specific signals, demographic heterogeneity, and time-to-onset (TTO) patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS data from Q3 2005 to Q1 2026 were retrospectively analyzed. Reports were included when carboplatin or cisplatin was recorded as the primary suspect drug and lung cancer was listed as the indication. Disproportionality analyses were performed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). Positive Preferred Term (PT) signals were further screened for clinical relevance. TTO was summarized using median and interquartile range (IQR), and Weibull models were fitted to assess temporal failure patterns. Age- and sex-stratified analyses and exclusion-based sensitivity analyses were also conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 12,045 eligible case reports were included, comprising 10,159 carboplatin-associated and 1,886 cisplatin-associated reports. Carboplatin-related reports were mainly characterized by hematologic and infection-related signals, including anaemia, neutropenia, pancytopenia, thrombocytopenia, febrile neutropenia, leukopenia, and neutropenic sepsis, together with hepatobiliary and hypersensitivity-related signals. Cisplatin-related reports showed broader renal, vascular, auditory or vestibular, gastrointestinal, and electrolyte-related signals, including renal salt-wasting syndrome. Valid TTO information was available for 4,487 carboplatin-associated and 823 cisplatin-associated reports. Median TTO was 25\u202fdays for carboplatin (IQR, 8\u201367\u202fdays) and 21\u202fdays for cisplatin (IQR, 8\u201362\u202fdays). More than half of reports with valid TTO occurred within 0\u201330\u202fdays after treatment initiation: 55.0% for carboplatin and 59.7% for cisplatin. Weibull analysis supported an early-failure reporting pattern for both agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Carboplatin and cisplatin showed distinct but overlapping adverse-event reporting profiles in lung cancer. These findings may support organ-specific and time-stratified safety monitoring, particularly during the first treatment cycle. However, they should be interpreted as pharmacovigilance signals rather than estimates of incidence, absolute risk, or causality, and require further prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1846025","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:53:34Z","timestamp":1784699614000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative safety signals of carboplatin and cisplatin in lung cancer: a pharmacovigilance study based on FAERS"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiale","family":"Yang","sequence":"first","affiliation":[{"name":"Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changbing","family":"Quan","sequence":"additional","affiliation":[{"name":"Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[{"name":"Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbing","family":"Cai","sequence":"additional","affiliation":[{"name":"Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Second Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung Cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/jco.21.01881","article-title":"Extensive-stage small-cell lung cancer: first-line and second-line treatment options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e202312402","DOI":"10.1002\/anie.202312402","article-title":"Nucleic acid-based electrochemical sensors facilitate the study of DNA binding by platinum (II)-based Antineoplastics","volume":"63","author":"Wu","year":"2024","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"108642","DOI":"10.1016\/j.pharmthera.2024.108642","article-title":"Cisplatin in the era of PARP inhibitors and immunotherapy","volume":"258","author":"Duan","year":"2024","journal-title":"Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"6928","DOI":"10.3390\/ijms21186928","article-title":"Comparative study of the mode of action of clinically approved platinum-based chemotherapeutics","volume":"21","author":"Schoch","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1021\/tx060058c","article-title":"Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry","volume":"19","author":"Hah","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1436896","DOI":"10.3389\/fneph.2024.1436896","article-title":"Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches","volume":"4","author":"Lyrio","year":"2024","journal-title":"Front Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e93093","DOI":"10.7759\/cureus.93093","article-title":"Comparative efficacy and cycle-wise toxicity of paclitaxel-carboplatin versus gemcitabine-cisplatin in stage IV non-small cell lung cancer (NSCLC): a quasi-experimental study in Bangladesh","volume":"17","author":"Bin Sharif","year":"2025","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/s1470-2045(24)00507-2","article-title":"Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2\/3 trial","volume":"25","author":"Mell","year":"2024","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2147\/rru.S554029","article-title":"Clinical outcomes of Avelumab maintenance following full-dose, reduced-dose cisplatin, or carboplatin-based chemotherapy in advanced urothelial carcinoma","volume":"17","author":"Furubayashi","year":"2025","journal-title":"Res Rep Urol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e70276","DOI":"10.1111\/cts.70276","article-title":"Critical roles for modeling and simulation and real-world evidence to inform challenges in clinical trial diversity planning","volume":"18","author":"Kadambi","year":"2025","journal-title":"Clin Transl Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"102915","DOI":"10.1016\/j.eclinm.2024.102915","article-title":"Real-world data: bridging the gap between clinical trials and practice","volume":"78","author":"Wilson","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1012093","DOI":"10.3389\/fonc.2022.1012093","article-title":"Platinum drugs-related safety profile: the latest five-year analysis from FDA adverse event reporting system data","volume":"12","author":"Feng","year":"2022","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e46044","DOI":"10.1097\/md.0000000000046044","article-title":"Comprehensive pharmacovigilance of phytoalkaloid chemotherapeutics: signal detection and time-to-onset analysis based on FAERS","volume":"104","author":"Song","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1590738","DOI":"10.3389\/fmed.2025.1590738","article-title":"Real-world safety of carboplatin in non-small cell lung cancer: a retrospective signal detection and subgroup analysis based on the FAERS database","volume":"12","author":"Wang","year":"2025","journal-title":"Front Med (Lausanne)."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1844057","DOI":"10.3389\/fphar.2026.1844057","article-title":"Risk factors for drug-related impaired gastric emptying: a pharmacovigilance analysis of the FDA adverse event reporting system","volume":"17","author":"Chen","year":"2026","journal-title":"Front Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"31339","DOI":"10.1038\/s41598-025-16384-9","article-title":"A real-world safety signal detection study of ondansetron based on FAERS reports from 2014 to 2024","volume":"15","author":"Yang","year":"2025","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1762761","DOI":"10.3389\/fphar.2026.1762761","article-title":"Spectrum and signals of medication-associated cognitive disorder: a comprehensive disproportionality analysis with cross-database validation","volume":"17","author":"Wen","year":"2026","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e0341855","DOI":"10.1371\/journal.pone.0341855","article-title":"Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: a 20-year signal detection study based on the FAERS database","volume":"21","author":"Wang","year":"2026","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1643906","DOI":"10.3389\/fphar.2026.1643906","article-title":"Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS)","volume":"17","author":"Yu","year":"2026","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e47947","DOI":"10.1097\/md.0000000000047947","article-title":"Data mining and analysis of adverse drug events of propofol in the general population and the elderly based on the US Food and Drug Administration adverse event reporting system","volume":"105","author":"Liu","year":"2026","journal-title":"Medicine (Baltimore)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e0338188","DOI":"10.1371\/journal.pone.0338188","article-title":"A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib","volume":"20","author":"Shi","year":"2025","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2611182","DOI":"10.1080\/20523211.2025.2611182","article-title":"Signal mining and safety profile analysis of lapatinib: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"19","author":"Cerbito","year":"2026","journal-title":"J Pharm Policy Pract"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.7150\/ijms.8.487","article-title":"Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations","volume":"8","author":"Sakaeda","year":"2011","journal-title":"Int J Med Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1773599","DOI":"10.3389\/fmed.2026.1773599","article-title":"A multi-database pharmacovigilance study reveals distinctive immunosuppressive and opportunistic infection disproportionality signals with bevacizumab and temozolomide combination therapy in glioblastoma","volume":"13","author":"Yu","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1837640","DOI":"10.3389\/fimmu.2026.1837640","article-title":"Sex-specific reporting patterns and onset timing of immune-related adverse events associated with nivolumab and pembrolizumab: a dual-database pharmacovigilance analysis","volume":"17","author":"Bai","year":"2026","journal-title":"Front Immunol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"17301","DOI":"10.1038\/s41598-025-02359-3","article-title":"A disproportionality analysis of adverse events associated with ertapenem using the FAERS database from 2004 to 2024","volume":"15","author":"Tang","year":"2025","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"18738","DOI":"10.1038\/s41598-025-02426-9","article-title":"Postmarketing safety evaluation of pemetrexed using FAERS and JADER databases","volume":"15","author":"Lv","year":"2025","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1384906","DOI":"10.3389\/fonc.2024.1384906","article-title":"Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer","volume":"14","author":"Chen","year":"2024","journal-title":"Front Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1728163","DOI":"10.3389\/fimmu.2025.1728163","article-title":"Lung cancer immunotherapy in 2025: where we stand and what comes next?","volume":"16","author":"Han","year":"2025","journal-title":"Front Immunol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2217\/fon-2023-0513","article-title":"The impact of myelosuppression on quality of life of patients treated with chemotherapy","volume":"20","author":"Crawford","year":"2024","journal-title":"Future Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"101734","DOI":"10.1016\/j.toxrep.2024.101734","article-title":"Protective effect of Ficus capensis lyophilized extract against carboplatin-induced liver injury via inhibition of oxidative stress and inflammation in rats","volume":"13","author":"Nwadibia","year":"2024","journal-title":"Toxicol Rep"},{"key":"ref35","volume-title":"StatPearls","author":"Raza","year":"2026"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"606","DOI":"10.12788\/fp.0198","article-title":"Cisplatin-induced acute kidney injury and renal salt wasting syndrome","volume":"38","author":"Russo","year":"2021","journal-title":"Fed Pract"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.34067\/kid.0000000000000394","article-title":"Renal salt wasting following cisplatin","volume":"5","author":"Latcha","year":"2024","journal-title":"Kidney360"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1704489","DOI":"10.3389\/fgene.2025.1704489","article-title":"The risk factors for chemotherapy myelosuppression in breast cancer: a systematic review and meta-analysis","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Genet"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/practneurol-2021-003194","article-title":"Posterior reversible encephalopathy syndrome (PRES): diagnosis and management","volume":"22","author":"Triplett","year":"2022","journal-title":"Pract Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/ph15020255","article-title":"Gender and sex-related differences in Normal tissue effects induced by platinum compounds","volume":"15","author":"Marcu","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"3507721","DOI":"10.1155\/2022\/3507721","article-title":"Sex difference in cisplatin-induced nephrotoxicity: laboratory and clinical findings","volume":"2022","author":"Eshraghi-Jazi","year":"2022","journal-title":"J Toxicol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e77769","DOI":"10.7759\/cureus.77769","article-title":"Accelerated coronary artery disease in a patient with advanced lung cancer: interplay of cancer, inflammation, and treatment effects","volume":"17","author":"Tolu-Akinnawo","year":"2025","journal-title":"Cureus"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1389814","DOI":"10.3389\/fphar.2024.1389814","article-title":"Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12885-021-08136-5","article-title":"Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials","volume":"21","author":"Huang","year":"2021","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1846025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:14:46Z","timestamp":1786540486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1846025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":44,"alternative-id":["10.3389\/fmed.2026.1846025"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1846025","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1846025"}}